Sven-Erik Dahlén
Corporate Officer/Principal en Karolinska Institutet .
Perfil
Sven-Erik Dahlén is a Professor at Karolinska Institutet.
He was previously the Director at Resistentia Pharmaceuticals AB from 2005 to 2010.
Cargos activos de Sven-Erik Dahlén
Empresas | Cargo | Inicio |
---|---|---|
Karolinska Institutet | Corporate Officer/Principal | - |
Antiguos cargos conocidos de Sven-Erik Dahlén.
Empresas | Cargo | Fin |
---|---|---|
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | Director/Board Member | 24/06/2010 |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | Health Technology |
- Bolsa de valores
- Insiders
- Sven-Erik Dahlén